• Explore /
  • Poster
  • / Phase I dose-escalation study of PSMA-targeted alpha emitter <sup>225</sup>Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

Phase I dose-escalation study of PSMA-targeted alpha emitter 225Ac-J591 in men with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Video & Slides Poster

Authors

Scott Tagawa

Scott T. Tagawa

Weill Cornell Medicine, New York, NY

Scott T. Tagawa , Joseph Osborne , Escarleth Fernandez , Charlene Thomas , Muhammad Junaid Niaz , Amy Ciriaco , Shankar Vallabhajosula , Panagiotis J. Vlachostergios , Ana M. Molina , Cora N. Sternberg , Sharon Singh , John Babich , David M. Nanus , Karla V. Ballman , Neil Harrison Bander

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2020 ASCO Virtual Scientific Program

Session Type

Poster Session

Session Title

Genitourinary Cancer—Prostate, Testicular, and Penile

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Prostate Cancer - Advanced Disease

Clinical Trial Registration Number

NCT03276572

Citation

J Clin Oncol 38: 2020 (suppl; abstr 5560)

DOI

10.1200/JCO.2020.38.15_suppl.5560

Abstract #

5560

Poster Bd #

141

Abstract Disclosures

Similar Posters

First Author: Scott T. Tagawa

First Author: Michael Sun

First Author: Scott T. Tagawa

First Author: Panagiotis J. Vlachostergios